88 related articles for article (PubMed ID: 16361854)
21. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
22. Altered carnitine metabolism in dialysis patients with reduced physical function may be due to dysfunctional fatty acid oxidation.
Murphy WJ; Steiber A; Connery GC; Carder J; Spry L; Hoppel C
Nephrol Dial Transplant; 2012 Jan; 27(1):304-10. PubMed ID: 21765185
[TBL] [Abstract][Full Text] [Related]
23. Carnitine supplementation in premature neonates: effect on plasma and red blood cell total carnitine concentrations, nutrition parameters and morbidity.
Crill CM; Storm MC; Christensen ML; Hankins CT; Bruce Jenkins M; Helms RA
Clin Nutr; 2006 Dec; 25(6):886-96. PubMed ID: 16808989
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the effect of intravenous l-carnitine on quality of life in chronic hemodialysis patients.
Semeniuk J; Shalansky KF; Taylor N; Jastrzebski J; Cameron EC
Clin Nephrol; 2000 Dec; 54(6):470-7. PubMed ID: 11140808
[TBL] [Abstract][Full Text] [Related]
25. The effect of L-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients.
Suchitra MM; Ashalatha VL; Sailaja E; Rao AM; Reddy VS; Bitla AR; Sivakumar V; Rao PV
Saudi J Kidney Dis Transpl; 2011 Nov; 22(6):1155-9. PubMed ID: 22089773
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
Desai J; Demetri GD
Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
Mohini R
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
[TBL] [Abstract][Full Text] [Related]
29. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
30. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
McGahan L
Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
[TBL] [Abstract][Full Text] [Related]
31. Effects of L-carnitine on oxidative stress responses in patients with renal disease.
Fatouros IG; Douroudos I; Panagoutsos S; Pasadakis P; Nikolaidis MG; Chatzinikolaou A; Sovatzidis A; Michailidis Y; Jamurtas AZ; Mandalidis D; Taxildaris K; Vargemezis V
Med Sci Sports Exerc; 2010 Oct; 42(10):1809-18. PubMed ID: 20216464
[TBL] [Abstract][Full Text] [Related]
32. Effect of L-carnitine administration on erythropoietin use in thalassemic minor haemodialysis patients.
Di Iorio BR; Guastaferro P; Cillo N; Cucciniello E; Bellizzi V
Nephrol Dial Transplant; 2007 Mar; 22(3):954-5; author reply 955-6. PubMed ID: 17132710
[No Abstract] [Full Text] [Related]
33. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
34. Carnitine action on red blood cell osmotic resistance in hemodialysis patients.
Vlassopoulos DA; Hadjiyannakos DK; Anogiatis AG; Evageliou AE; Santikou AV; Noussias CV; Papandreou PT; Hadjiconstantinou VE
J Nephrol; 2002; 15(1):68-73. PubMed ID: 11936429
[TBL] [Abstract][Full Text] [Related]
35. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference.
Eknoyan G; Latos DL; Lindberg J;
Am J Kidney Dis; 2003 Apr; 41(4):868-76. PubMed ID: 12666074
[TBL] [Abstract][Full Text] [Related]
36. Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: A double-blind randomized trial.
Thomas S; Fischer FP; Mettang T; Pauli-Magnus C; Weber J; Kuhlmann U
Am J Kidney Dis; 1999 Oct; 34(4):678-87. PubMed ID: 10516349
[TBL] [Abstract][Full Text] [Related]
37. The effect of levocarnitine supplementation on dialysis-related hypotension: A systematic review, meta-analysis, and trial sequential analysis.
Chewcharat A; Chewcharat P; Liu W; Cellini J; Phipps EA; Melendez Young JA; Nigwekar SU
PLoS One; 2022; 17(7):e0271307. PubMed ID: 35834513
[TBL] [Abstract][Full Text] [Related]
38. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia].
Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S
Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880
[TBL] [Abstract][Full Text] [Related]
40. Effects of L-carnitine on dialysis-related hypotension and muscle cramps: a meta-analysis.
Lynch KE; Feldman HI; Berlin JA; Flory J; Rowan CG; Brunelli SM
Am J Kidney Dis; 2008 Nov; 52(5):962-71. PubMed ID: 18706751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
